2024
Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC).
Labaki C, Alchoueiry M, Bi K, Zhang L, Hobeika C, Bakouny Z, El Ahmar N, Matar S, Priolo C, Khabibullin D, Schindler N, Camp S, Saliby R, Saad E, Signoretti S, Van Allen E, Shukla S, Henske E, Choueiri T, Braun D. Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC). Journal Of Clinical Oncology 2024, 42: 476-476. DOI: 10.1200/jco.2024.42.4_suppl.476.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsAnti-tumor immunityCell of originScRNA-seq dataPutative cell of originHLA class I genesCD8+Class I genesPD-1T cellsI geneSingle-cell T-cell receptorPoor responseResponse to immune checkpoint inhibitorsExpression of HLA class I genesInfiltration of CD8+Infiltration of T cellsCD4+ T cellsDegree of clonal expansionDownregulation of antigen presentationProportion of CD8+T cell clonotypesChromophobe renal carcinomaMolecular determinantsProtein processing pathway
2023
Antigenic targets in clear cell renal cell carcinoma
Schindler N, Braun D. Antigenic targets in clear cell renal cell carcinoma. Kidney Cancer 2023, 7: 81-91. PMID: 38014393, PMCID: PMC10475986, DOI: 10.3233/kca-230006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsRenal cell carcinomaImmune checkpoint inhibitorsCell carcinomaImmune-related adverse effectsEffective anti-tumor immunityAdvanced renal cell carcinomaClear cell renal cell carcinomaAntigen-directed immunotherapySafety of immunotherapyClear cell histologyAnti-tumor immunityCell renal cell carcinomaCheckpoint inhibitorsCell histologyICI responseMost patientsNeoantigen loadCurrent therapiesAntigenic targetsLong-term benefitsMutation burdenTarget antigenAdverse effectsAntigenImmunotherapy